Mandatory Rest Period: MOVED!

2005-06-09

COPAXONE Produced Significantly Greater Reduction in Relapse Rate Compared to Beta Interferon Therapies

Results from a still on-going independent study published in the European Journal of Neurology demonstrate COPAXONE(R) (glatiramer acetate injection) is associated with lower relapse rates than interferon therapies in patients with relapsing-remitting multiple sclerosis (RRMS). Compared to interferon beta 1b (Betaferon(R)), interferon beta 1a (Avonex(R)), and 22 microgram interferon beta 1a (Rebif(R) 22), COPAXONE(R) produced a statistically significant greater reduction in annual relapse rates at 24 months after initiation of treatment versus pre-study rates. Additionally, a significantly higher percentage of patients remained on COPAXONE(R) for the duration of the study compared to the beta interferons.

0 Comments:

Post a Comment

<< Home